Ignis Therapeutics
Series A in 2021
Ignis Therapeutics is a life science company developing innovative therapies in the field of the central nervous system. With a strong commitment to self-discovery and a development strategy to advance the treatment paradigm, Ignis Therapeutics transforms the approach to treating CNS conditions. Ignis Therapeutics is dedicated to developing products that significantly improve the lives of patients while also providing additional therapeutic options for physicians.
Haoxinqing is an online medical service platform focusing on the fields of mental psychology and chronic disease management.
Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases.
Lyvgen Biopharma is a cross-linking-dependent antibody platform. The company also provides tumor immune agonistic antibody, local activation of the tumor microenvironment, and synthetic biology engineering services.
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases.
MitrAssist introduces a minimally invasive approach to MR treatment. Its mitral valve implant works in unison with the natural mitral valve without harming its functionality. MitrAssist has developed a new approach to treating MR that is neither repair nor replacement. Instead, its proprietary valve implant is placed on top of the natural valve to work in unison with it and to enhance valve functionality. MitrAssist’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients. It has significant advantages over minimally invasive solutions – both existing and in development.
Kira Pharmaceuticals their treatment gives pioneering complement drug discovery to deliver transformative therapies for people with complement-mediated diseases.
Haoxinqing is an online medical service platform focusing on the fields of mental psychology and chronic disease management.
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Guoke Hengtai (Beijing) Medical Technology Co., Ltd. was established in February 2013 and is affiliated to Oriental Science and Technology Holding Group Co., Ltd. (hereinafter referred to as “Oriental Instrument”), a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. It is headquartered in Yizhuang Economic and Technological Development Zone, Beijing. . Since the establishment of Guoke Hengtai for 4 years, the company has experienced two rounds of investment in A and B, and its performance has continued to grow at a high speed, with a compound annual growth rate of over 50%. In 2017, the company officially launched the IPO listing journey.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeper and more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain
HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis. The company was founded in 2019 and is based in New York.
Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states.
Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates. Its technology uses machine-learning-based image analysis tools for visualizing condensates and offers an engine for genetically linked condensatopathy which is a collection of engineered cell lines with trackable condensates to prevent harmful protein sequestration, helping healthcare providers to have access to new therapies to address unmet needs. The company was founded in 2018 and is headquartered in Boston, Massachusetts.
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins.
Coherent Biopharma is a pahrmaceutical based agency.
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases. The company develops a proprietary product engine that is employed to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairment and disability. It is focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. Founded in 2016, the company is based in Cambridge, Massachusetts, United States.
WiseTek is a medical device company that develops minimally invasive surgical instruments. The company's products include disposable ureteroscopic catheters, cystoscopic catheters, disposable electronic bronchoscopes, and endoscope image processors. The company's goal is to provide minimally invasive surgical tools for the eyes that will make future surgical procedures and medical diagnoses safer, more accurate, and less invasive.
GloriousMed Technology is a Healthcare company.
Curon Biopharma is a developer of drugs intended designed for immuno-oncology therapies. The company's drugs consist of multiple class-leading cancer immunotherapeutic agents in the world that could address the shortcomings of current cancer treatment paradigm, enabling a physician to provide advanced cancer immunotherapies to their patients.
Lyvgen Biopharma is a cross-linking-dependent antibody platform. The company also provides tumor immune agonistic antibody, local activation of the tumor microenvironment, and synthetic biology engineering services.
ITeos Therapeutics is a private biotechnology company targeting the metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology, therapeutic cancer vaccines, cancer biology, and translational medicine in cancer. iTeos endeavors to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies).
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating mini proteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments. FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. It is laser-focused and unstoppable in its mission to deliver a new class of medicines to patients and their families to bring them years to life and life to years.
Yiyao is also knwon as 111.com.cn. Yiyao is an online drug superstore where patients can buy over-the-counter medications, traditional Chinese remedies, and a variety of other health products including everything from sex toys to diet pills. 111.com.cn operates as an online portal for selling pharmaceutical products.
Shenzhen Kangtai Biological Products Co., Ltd. is a listed company integrating research, development, production and sales of biological products.the company has R&D centers and industrial bases in Shenzhen and Beijing. It is one of the major hepatitis B vaccine manufacturers in China.The company's main business is the development, production and sales of human vaccines. The product categories cover Class I and Class II vaccines. The main products are recombinant hepatitis B vaccine (Saccharomyces cerevisiae), Haemophilus influenzae type b conjugate vaccine, and measles and rubella. Live attenuated vaccine, cell-free white-breaking Haemophilus influenzae type b combined vaccine, 23- valent pneumococcal polysaccharide vaccine and other products.
Forerunner Medical (Shanghai) Co., Ltd. develops and manufactures medical devices for minimally invasive treatment. It primarily develops and produces low-temperature plasma radiofrequency generators and electrodes for sport medicine, disk demo-pression, and ENT treatment applications. Its products include plasma radiofrequency systems; and electrodes for joint, spine, cervical, lumbar, transforaminal endoscopic operation, and ENT treatment applications. The company was founded in 2009 and is based in Shanghai, China.
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases. The Company’s portfolio selectively targets shared critical pathways that are the root cause of disease. Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integrated biotechnology company, helping millions of patients worldwide. Viela Bio is located in Gaithersburg, Maryland.
Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery. Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company's proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications.
NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeper and more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.
Medeor Therapeutics is a developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.
Guangzhou Baseline Medical is committed to building a world-class clinical application of high-throughput sequencing and R & D platform to become the leading global provider of precision medical solutions. The company's core team has more than 20 years of senior industry experience, involved in cancer genomics, genetics and bioinformatics and other fields. Based on its core technical advantages, the Company aims at precision medicine, establishes a cooperative relationship with middle and downstream enterprises in the industry, and forms a complete industrial chain from academic research to clinical product transformation. It has also established close cooperation with many large-scale third-party inspection agencies including Illumina, Well-known domestic and foreign hospitals and research institutes to establish cooperative relations, the development of a series of independent intellectual property rights and international competitiveness of clinical testing products for patients, doctors and medical institutions to provide accurate, convenient and comprehensive services.
Zhejiang Qilian Network Technology (abbreviation: Qilian Health) was established in 2014. It is located in Hangzhou, the most dynamic Internet city, formerly known as the Wireless Business Division of Lianlian Group. It has focused on the medical Internet industry for many years and is committed to Internet technology has established a large platform for serving patients, doctors, and hospitals. With the mission of “creating the health services around us”, we strive to realize the vision of “making life more healthy”. Currently, Qilian Health has completed billion-round B-round financing, and its business scope has expanded from hospital WIFI, patient-side APP, and medical-end APP to providing one-stop hospital Internet of Things application solutions. At the beginning of its establishment, Qilian HealthTaking the hospital WIFI as an entry point, it has invested a lot of resources to deepen the hospital scene services. With the world's leading professional technology, industry-leading product portfolio, and top-notch partners, it has successfully served thousands of large-scale general hospitals. Currently, it has signed more than 1,700 hospitals in 245 cities (including more than 400 triple-A hospitals), covering more than 900 million outpatient visits, and the total number of AP coverage is nearly 100,000, which exceeds the total number of competitors in the industry and has become China's largest hospital WIFI service provider. With high-quality hospital WIFI as the carrier, Qilian Health has designed a modular user-centric service design and launched the Medicare Xiaobian Medical Aid APP, a corporate employee health management platform, and a health APP. Xiaoyi Medical Aid App is positioned as a medical aide and provides medical staff with free access to the Internet, electronic cloud cases, medical tools, case exchanges, clinical guidelines and other medical tools. At present, Xiaoyu Medical Assistance APP installs 750,000+ users and registers medical personnel 170,000+. Health App, which assembles top medical resources in the country and relies on artificial intelligence to accurately interpret personal health data in a comprehensive manner. It customizes personalized health management programs, differentiated exercise prescriptions and balanced meal plans for companies, builds corporate health service ecosystem, and enables employees to Healthier and more dynamic. Based on the absolute market share in the hospital's Wi-Fi market, Qilian has quickly and effectively deployed hospital Internet of Things and has reached a strategic cooperation with well-known equipment manufacturer Foxconn, and will jointly invest in establishing a joint venture to provide IoT application solutions for medical institutions. Qilian is responsible for the business development, signing, and development and implementation of Internet of Things projects. Foxconn provides special equipment, platforms, and building technologies for hospital Internet of Things, centering on outpatient and hospitalization scenarios, and using WIFI, LoRa and other Internet of Things technologies to achieve The opening of the hospital's resources and services helps medical institutions reduce operating costs, improve service efficiency, and increase revenue. With the acceleration of consumer upgrades and aging, and the rapid development of network technology, “Internet+Medical” and “Internet of Things+Medical” have broad prospects and space. In the future, Qilian will deepen its cultivation of big data and medical and health industries. Through cooperation with professional companies and hospitals in general, Qilian will rapidly grow and expand and will create healthy services around them to make life healthier.
"Suzhou Jiecheng Medical Technology Co., Ltd." is a high-tech medical technology company with completely independent intellectual property rights and its patented technology is in a leading position in the world. The company was established in September 2009. The R&D team consists of Cardiologist Zhang Ji and several domestic and foreign R&D experts. The company's leading project is the development and production of the innovative "J-Valve Precision Positioning Heart Valve Implant System" technology. "J-Valve Precise Positioning Heart Valve Implant System" is a minimally invasive surgical technique that eliminates the need to open a chest and eliminates extracorporeal blood circulation. It can significantly reduce patient's surgical trauma, shorten postoperative recovery time, reduce patient's pain, and reduce The requirements of the patient's physical condition, thereby expanding the range of application of the disease, improving the efficacy of treatment, reducing the cost of surgery, so that the majority of patients need to replace the heart valve can be treated. Other similar products can only be implanted into the heart through the use of imaging technology. The J-Valve system can completely rely on its own positioning device to assist doctors in performing valve replacement surgery, thereby reducing the risk of surgery, easier to operate and master, and simplifying the heart valve Replacement process. The above advantages will help reduce the overall cost of the country's health care system, promote the reform of the health care system, reduce medical costs, and save social medical resources. At the same time, drastic changes in the long-term dependence on